In-Line Diagnostics, Inc.
This article was originally published in The Gray Sheet
Executive SummaryRaises $20 mil. in private equity financing. The Salt Lake City firm makes Crit-Line monitors to non-invasively measure hematocrit, oxygen saturation and changes in blood volume. The funds "will allow the company to expand its renal care operations and accelerate development of its other proprietary non-invasive technologies across a variety of medical specialties and applications," states Chairman Robert Steuer. The firm simultaneously announces Aug. 11 FDA 510(k) clearance of its Crit-Scan transcutaneous hematocrit monitoring device. The Crit-Scan is "the first non-invasive device used to measure whole blood hematocrit," the firm claims, and "virtually eliminates the need for finger sticks associated with blood tests and blood donation"
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.